BH3 Peptide Profiling for Cancer Cell Chemosensitivity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective way to predict cellular sensitivity to therapeutic agents, particularly in cancer cells, as they rely on indirect indicators and do not directly assess the cellular response to BH3 domain peptides, which are crucial for apoptosis induction.
Innovation Solution
The method involves contacting cancer cells or their components with BH3 domain peptides to induce apoptosis and creating a BH3 profile, comparing it to a control profile to determine sensitivity, using peptides derived from BH3 domains of proteins like BID, BIM, BAD, BIK, NOXA, PUMA, and HRK, and detecting cytochrome c release to assess mitochondrial sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current indirect methods are used to predict cellular sensitivity, then the prediction process is simpler, but the prediction accuracy and reliability are insufficient
Solution Approach 1:
The patent segments the complex prediction process into distinct functional components: (1) contacting cells with BH3 domain peptides, (2) detecting cytochrome c release as a specific readout, and (3) generating a BH3 sensitivity profile. This segmentation allows each component to be optimized independently while maintaining overall system accuracy and reliability.
Solution Approach 2:
The patent introduces cytochrome c release as an intermediary marker that directly reflects mitochondrial sensitivity to BH3 peptides. This intermediary provides a measurable, quantifiable signal that accurately represents cellular chemosensitivity, bridging the gap between cellular response and predictive measurement.
2Reliability
If direct assessment of cellular response to BH3 peptides is implemented, then the reliability of sensitivity prediction improves, but the complexity of the method increases
Solution Approach 1:
The patent employs a self-service approach where the cell's own mitochondrial machinery (cytochrome c release) serves as the direct readout for sensitivity assessment. This eliminates the need for external indicators or indirect proxies, thereby enhancing reliability while keeping the methodology straightforward and biologically direct.
Solution Approach 2:
The patent changes the measurement parameter from indirect cellular responses to direct cytochrome c release quantification. This parameter change enables reliable sensitivity prediction by focusing on a specific, measurable biochemical event that directly reflects mitochondrial apoptosis pathway activation in response to BH3 peptides.
3Measurement precision
If a panel of BH3 domain peptides is used to create a BH3 profile, then the precision of therapeutic agent sensitivity prediction increases, but the time and resources required increase
Solution Approach 1:
The patent performs preliminary action by establishing a comprehensive BH3 sensitivity profile before therapeutic decision-making. This upfront profiling, though time-consuming, provides precise predictive information that guides subsequent treatment choices, ultimately saving time by avoiding trial-and-error therapeutic approaches.
Solution Approach 2:
The BH3 profile generated using multiple peptides serves multiple functions: it predicts sensitivity to various therapeutic agents, identifies dominant anti-apoptotic proteins, and guides treatment selection. This multi-functionality justifies the initial time investment by providing comprehensive predictive information applicable to multiple therapeutic scenarios.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise prediction of cellular sensitivity to therapeutic agents by identifying primed cells that are dependent on anti-apoptotic proteins, enabling targeted treatment strategies and enhancing chemotherapy efficacy.
Implementation Method 1
contacting the cell or a cellular component (e.g., mitochondria) thereof with a BH3 domain peptide and detecting apoptosis
Implementation Method 2
detecting cytochrome c release to assess mitochondrial sensitivity
Data Source
AI summary
The present invention provides methods of determining cell sensitivity to a therapeutic agent.